Kupando
Germany-based biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases
Berlin, Germanywww.kupando.com ↗
Total raised
€23M
€23,000,000
Funding rounds
2
Investors
7
distinct backers
Active since
2022-09
latest 2026-03
Funding by year
EUR raised per year · 2026 YTDSignals
High confidenceRaise-next likelihood26
base rate 44% for Series A
- ▼ Raised very recently
- ▼ Down/flat last round
Exit likelihood12
base rate 12% (2+ rounds)
Timing: too soon vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-03-19 | Series A | €10M | Carma Fund,Brandenburg Kapital,High-Tech Gründerfonds,LifeCare Partners,Remiges Ventures,Ventura Biomed Investors | View deal → |
| 2022-09-26 | Series A | €13M | Brandenburg Kapital,family office,High-Tech Gründerfonds,LifeCare Partners,Remiges Ventures,Ventura Biomed Investors | View deal → |
Investors
7Related news
- Kupando Raises €13M in Series A Fundingfinsmes.com · 2022-09
- finsmes.com
Similar companies
same sector or country- Delivery Hero€7.3BGermany · E-commerce
- Enpal€4.6BGermany · Cleantech
- Auxmoney€3.5BGermany · Fintech
- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Celonis€2.1BGermany · Software